Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
The move comes after a death in the Alpha-3 cema-cel study.
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Jazz’s Chimerix buy faces its big test.
The first data are dribbled out, but cross-trial comparisons look uninspiring.